457 related articles for article (PubMed ID: 23519708)
1. Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis.
Almandil NB; Liu Y; Murray ML; Besag FM; Aitchison KJ; Wong IC
Paediatr Drugs; 2013 Apr; 15(2):139-50. PubMed ID: 23519708
[TBL] [Abstract][Full Text] [Related]
2. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
3. Quetiapine versus other atypical antipsychotics for schizophrenia.
Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
[TBL] [Abstract][Full Text] [Related]
4. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.
Rummel-Kluge C; Komossa K; Schwarz S; Hunger H; Schmid F; Lobos CA; Kissling W; Davis JM; Leucht S
Schizophr Res; 2010 Nov; 123(2-3):225-33. PubMed ID: 20692814
[TBL] [Abstract][Full Text] [Related]
5. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
6. Aripiprazole versus other atypical antipsychotics for schizophrenia.
Komossa K; Rummel-Kluge C; Schmid F; Hunger H; Schwarz S; El-Sayeh HG; Kissling W; Leucht S
Cochrane Database Syst Rev; 2009 Oct; (4):CD006569. PubMed ID: 19821375
[TBL] [Abstract][Full Text] [Related]
7. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.
Correll CU; Manu P; Olshanskiy V; Napolitano B; Kane JM; Malhotra AK
JAMA; 2009 Oct; 302(16):1765-73. PubMed ID: 19861668
[TBL] [Abstract][Full Text] [Related]
8. Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.
Wang LJ; Ree SC; Huang YS; Hsiao CC; Chen CK
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():260-6. PubMed ID: 23085073
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
Stroup TS; McEvoy JP; Ring KD; Hamer RH; LaVange LM; Swartz MS; Rosenheck RA; Perkins DO; Nussbaum AM; Lieberman JA;
Am J Psychiatry; 2011 Sep; 168(9):947-56. PubMed ID: 21768610
[TBL] [Abstract][Full Text] [Related]
10. Aripiprazole versus other atypical antipsychotics for schizophrenia.
Khanna P; Komossa K; Rummel-Kluge C; Hunger H; Schwarz S; El-Sayeh HG; Leucht S
Cochrane Database Syst Rev; 2013 Feb; (2):CD006569. PubMed ID: 23450570
[TBL] [Abstract][Full Text] [Related]
11. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials.
Schneider LS; Dagerman K; Insel PS
Am J Geriatr Psychiatry; 2006 Mar; 14(3):191-210. PubMed ID: 16505124
[TBL] [Abstract][Full Text] [Related]
13. The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia.
Meyer JM; Rosenblatt LC; Kim E; Baker RA; Whitehead R
J Clin Psychiatry; 2009 Mar; 70(3):318-25. PubMed ID: 19192469
[TBL] [Abstract][Full Text] [Related]
14. Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials.
Pringsheim T; Lam D; Ching H; Patten S
Drug Saf; 2011 Aug; 34(8):651-68. PubMed ID: 21751826
[TBL] [Abstract][Full Text] [Related]
15. A Meta-Analysis of Antipsychotic-Induced Hypo- and Hyperprolactinemia in Children and Adolescents.
Krøigaard SM; Clemmensen L; Tarp S; Pagsberg AK
J Child Adolesc Psychopharmacol; 2022 Sep; 32(7):374-389. PubMed ID: 36074098
[No Abstract] [Full Text] [Related]
16. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
Byerly MJ; Marcus RN; Tran QV; Eudicone JM; Whitehead R; Baker RA
Schizophr Res; 2009 Feb; 107(2-3):218-22. PubMed ID: 19038534
[TBL] [Abstract][Full Text] [Related]
17. Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.
Jin H; Shih PA; Golshan S; Mudaliar S; Henry R; Glorioso DK; Arndt S; Kraemer HC; Jeste DV
J Clin Psychiatry; 2013 Jan; 74(1):10-8. PubMed ID: 23218100
[TBL] [Abstract][Full Text] [Related]
18. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.
Mukundan A; Faulkner G; Cohn T; Remington G
Cochrane Database Syst Rev; 2010 Dec; (12):CD006629. PubMed ID: 21154372
[TBL] [Abstract][Full Text] [Related]
19. Aripiprazole alone or in combination for acute mania.
Brown R; Taylor MJ; Geddes J
Cochrane Database Syst Rev; 2013 Dec; (12):CD005000. PubMed ID: 24346956
[TBL] [Abstract][Full Text] [Related]
20. Second-generation antipsychotics for major depressive disorder and dysthymia.
Komossa K; Depping AM; Gaudchau A; Kissling W; Leucht S
Cochrane Database Syst Rev; 2010 Dec; (12):CD008121. PubMed ID: 21154393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]